P15ink4b plays a crucial role in murine lymphoid development and tumorigenesis

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 708-713

  Osei Sarfo, Kwame ^a,b   Perez de Castro, Ignacio ^a,c   Pellicer, Angel ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B; MUTANT PROTEIN; RAL GDS RELATED PROTEIN; RAS PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CELL MATURATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE INTERACTION; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; SURVIVAL RATE; THYMOCYTE; THYMUS LYMPHOMA; TRANSGENIC MOUSE;

EID: 84857980017     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs003     Document Type: Article

References (59)

1. Lowe,S.W. et al. (2004) Intrinsic tumour suppression. Nature, 432, 307-315.
2. Buday,L. et al. (2008) Many faces of Ras activation. Biochim. Biophys. Acta., 1786, 178-187.
3. Lloyd,A.C. et al. (1997) Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev., 11, 663-677.
4. Palmero,I. et al. (1998) p.19ARF links the tumour suppressor p.53 to Ras. Nature, 395, 125-126.
5. Malumbres,M. et al. (2000) Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p.15(INK4b). Mol. Cell. Biol., 20, 2915-2925.
6. Reed,A.L. et al. (1996) High frequency of p.16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56, 3630-3633.
7. Jarrard,D.F. et al. (1997) Deletional, mutational, and methylation analyses of CDKN2 (p.16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer, 19, 90-96.
8. Xing,E.P. et al. (1999) Mechanisms of inactivation of p.14ARF, p.15INK4b, and p.16INK4a genes in human esophageal squamous cell carcinoma. Clin. Cancer Res., 5, 2704-2713.
9. Rocco,J.W. et al. (2001) p.16(MTS-1/CDKN2/INK4a) in cancer progression. Exp. Cell Res., 264, 42-55.
10. Jen,J. et al. (1994) Deletion of p.16 and p.15 genes in brain tumors. Cancer Res., 54, 6353-6358.
11. Rasool,O. et al. (1995) p.15ink4B and p.16ink4 gene inactivation in acute lymphocytic leukemia. Blood, 85, 3431-3436.
12. Haidar,M.A. et al. (1995) p.16INK4A and p.15INK4B gene deletions in primary leukemias. Blood, 86, 311-315.
13. Gil,J. et al. (2006) Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol., 7, 667-677.
14. Martinez-Delgado,B. et al. (1997) Hypermethylation of a 5' CpG island of p 16 is a frequent event in non-Hodgkin's lymphoma. Leukemia, 11, 425-428.
15. Guo,S.X. et al. (2000) Hypermethylation of p.16 and p.15 genes and RB protein expression in acute leukemia. Leuk. Res., 24, 39-46.
16. Malumbres,M. et al. (1997) Inactivation of the cyclin-dependent kinase inhibitor p.15INK4b by deletion and de novo methylation with independence of p.16INK4a alterations in murine primary T-cell lymphomas. Oncogene, 14, 1361-1370.
17. Malumbres,M. et al. (1999) Hypermethylation of the cell cycle inhibitor p.15INK4b 3'-untranslated region interferes with its transcriptional regulation in primary lymphomas. Oncogene, 18, 385-396.
18. D'Adamo,D.R. et al. (1997) rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral. Oncogene, 14, 1295-1305.
19. Osei-Sarfo,K. et al. (2011) The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral. Oncogene, 30, 3661-3671.
20. Hernandez-Munoz,I. et al. (2000) The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways. Oncogene, 19, 2745-2757.
21. Hernandez-Munoz,I. et al. (2003) rgr oncogene: activation by elimination of translational controls and mislocalization. Cancer Res., 63, 4188-4195.
22. Leonardi,P. et al. (2002) Human rgr: transforming activity and alteration in T-cell malignancies. Oncogene, 21, 5108-5116.
23. Jimenez,M. et al. (2004) The Rgr oncogene induces tumorigenesis in transgenic mice. Cancer Res., 64, 6041-6049.
24. Takeuchi,S. et al. (1995) Analysis of a family of cyclin-dependent kinase inhibitors: p.15/MTS2/INK4B, p.16/MTS1/INK4A, and p.18 genes in acute lymphoblastic leukemia of childhood. Blood, 86, 755-760.
25. Cameron,E.E. et al. (1999) p.15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood, 94, 2445-2451.
26. Baur,A.S. et al. (1999) Frequent methylation silencing of p.15(INK4b) (MTS2) and p.16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood, 94, 1773-1781.
27. Drexler,H.G. (1998) Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p.15, p.16, p.18 and p.19 in human leukemialymphoma cells. Leukemia, 12, 845-859.
28. Martinez-Delgado,B. et al. (1998) Hypermethylation of p.15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia, 12, 937-941.
29. Laharanne,E. et al. (2010) CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod. Pathol., 23, 547-558.
30. Porcar,M. et al. (2007) A simple DNA extraction method suitable for PCR detection of genetically modified maize. J. Sci. Food Agric., 87, 2728-2731.
31. Latres,E. et al. (2000) Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J., 19, 3496-3506.
32. Mangues,R. et al. (1996) Activated N-ras oncogene and N-ras protooncogene act through the same pathway for in vivo tumorigenesis. Oncogene, 13, 1053-1063.
33. Garcia-Espana,A. et al. (2005) Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior. Cancer Res., 63, 1150-1157.
34. Guerrero,I. et al. (1984) Isolation, characterization, and chromosome assignment of mouse N-ras gene from carcinogen-induced thymic lymphoma. Science, 225, 1041-1043.
35. Germain,R.N. (2002) T-cell development and the CD4-CD8 lineage decision. Nat. Rev. Immunol., 2, 309-322.
36. Alberola-Ila,J. et al. (1995) Selective requirement for MAP kinase activation in thymocyte differentiation. Nature, 373, 620-623.
37. Boussiotis,V.A. et al. (1997) Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science, 278, 124-128.
38. Turner,H. et al. (1997) Distinct Ras effector pathways are involved in Fc epsilon R1 regulation of the transcriptional activity of Elk-1 and NFAT in mast cells. J. Exp. Med., 185, 43-53.
39. Genot,E. et al. (1996) Multiple p.21ras effector pathways regulate nuclear factor of activated T cells. EMBO J., 15, 3923-3933.
40. Turner,H. et al. (1998) Rac-1 regulates nuclear factor of activated T cells (NFAT) C1 nuclear translocation in response to Fcepsilon receptor type 1 stimulation of mast cells. J. Exp. Med., 188, 527-537.
41. Herman,J.G. et al. (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p.15INK4B. Cancer Res., 56, 722-727.
42. Teofili,L. et al. (2003) Hypermethylation of GpG islands in the promoter region of p.15(INK4b) in acute promyelocytic leukemia represses p.15(INK4b) expression and correlates with poor prognosis. Leukemia, 17, 919-924.
43. Wolff,L. et al. (2003) Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p.15(Ink4b)-deficient mice. Oncogene, 22, 9265-9274.
44. Ortega,S. M.M., Barbacid M. (2002). Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta., 1602, 73-87.
45. Laharanne,E. et al. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod. Pathol., 23, 547-558.
46. Agrawal,S. et al. (2007) DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res., 67, 1370-1377.
47. Daskalakis,M. et al. (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood, 100, 2957-2964.
48. Kisielow,P. et al. (1995) Development and selection of T cells: facts and puzzles. Adv. Immunol., 58, 87-95.
49. Hoffman,E. et al. (1996) Productive T-cell receptor B-chain gene rearrangement: coincident regulation of cell cycle clonality during development in vivo. Genes Dev., 10, 942-962.
50. von Boehmer,H. et al. (1999) Pleiotropic changes controlled by the pre-Tcell receptor. Curr. Opin. Immunol., 11, 135-147.
51. Hernandez,J.B. et al. (2010) Life and death in the thymus-cell death signaling during T cell development. Curr. Opin. Cell Biol., 22, 865-871.
52. Malumbres,M. et al. (1997) Isolation of high molecular weight DNA for reliable genotyping of transgenic mice. BioTechniques, 22, 1114-1119.
53. Malumbres,M. et al. (1998) RAS pathways to cell cycle control and cell transformation. Front. Biosci., 3, d887-d912.
54. Bertin,R. et al. (2003) CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p.21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer, 37, 44-57.
55. Garcia,M.J. et al. (2002) Different incidence and pattern of p.15INK4b and p.16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas. Am. J. Pathol., 161, 1007-1013.
56. El-Deiry,W.S. et al. (1993) WAF1, a potential mediator of p.53 tumor suppression. Cell, 75, 817-825.
57. Harper,J.W. et al. (1993) The p.21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
58. Martin-Caballero,J. et al. (2001) Tumor susceptibility of p.21(Waf1/Cip1)-deficient mice. Cancer Res., 61, 6234-6238.
59. De la Cueva,E. et al. (2006) Tumorigenic activity of p.21Waf1/Cip1 in thymic lymphoma. Oncogene, 25, 4128-4132.